frovatriptan / Generic mfg. - LARVOL DELTA

BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report. (PubMed, Br J Dermatol) - "The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is..."

Journal • Acute Kidney Injury • Alopecia • Atrial Fibrillation • Cardiovascular • Dermatology • Endocrine Disorders • Hematological Disorders • Herpes Zoster • Hypotension • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pneumococcal Infections • Pruritus • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Septic Shock • Varicella Zoster • Venous Thromboembolism • CRP • JAK3

BH19 'JAK in the box?' Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata. (PubMed, Br J Dermatol) - "The findings were synthesized to provide an overview of the safety profiles of baricitinib, ritlecitinib, deuruxolitinib, ivarmacitinib and other JAK inhibitors. Long-term safety data were scarce, with only one study (the phase IIb/III ALLEGRO trial on ritlecitinib) extending to 2 years, while others had follow-ups of 52 weeks or shorter...Given the chronic nature of AA and the potential for extended use of JAK inhibitors, further long-term studies are necessary to better assess the risks of malignancies, cardiovascular events and other rare but serious AEs associated with this drug class. Although short-term studies indicate efficacy and tolerability, the absence of longitudinal research underpins the need for cautious clinical use and informed patient decision making."

Journal • Review • Acne Vulgaris • Alopecia • Breast Cancer • Cardiovascular • Immunology • Infectious Disease • Melanoma • Myocardial Infarction • Oncology • Pain • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma

Comprehensive Evaluation of a Point-of-Care Testing Platform for Decentralized Primary Healthcare: Ensuring Analytical Quality Through Central Laboratory Oversight. (PubMed, Diagnostics (Basel)) - "This study aims to rigorously evaluate the analytical performance of the Allegro POCT system against established central laboratory reference methods to determine its suitability for decentralized healthcare settings...However, the significant biases for CHOL and TRIG underscore the indispensable role of central laboratory oversight in any POCT program. Rigorous initial validation and continuous quality monitoring under a robust governance framework are essential to ensure the reliability and clinical utility of POCT."

Journal • CRP

A Universal Augmentation Framework for Long-Range Electrostatics in Machine Learning Interatomic Potentials. (PubMed, J Chem Theory Comput) - "Here, we present LES as a standalone library, compatible with any short-range MLIP, and demonstrate its integration with methods such as MACE, NequIP, Allegro, CACE, CHGNet, and UMA...MACELES-OFF is more accurate than its short-range counterpart (MACE-OFF) trained on the same data set, predicts dipoles and BECs reliably, and has better descriptions of bulk liquids. By enabling efficient long-range electrostatics without directly training on electrical properties, LES paves the way for electrostatic foundation MLIPs."

Journal

Challenging the criteria: A case of unclassifiable trigeminal autonomic-like headache (EHF-EHC 2025) - "Frovatriptan provided fast relief, although some residual pain persists for up to 1 day. Indomethacin was tried but rapidly dismissed due to side effects...Despite the atypical pain duration, the presence of prominent autonomic signs and the partial response to Verapamil favours a diagnosis within the trigeminal autonomic cephalalgia spectrum, highlighting the diagnostic complexity of these entities. Disclosure:the patient gave her informed consent to publish her details."

Clinical • Mood Disorders • Pain

Efficacy and safety of almotriptan for treatment of menstrual migraine: A systematic review (EHF-EHC 2025) - "In a large trial (n=255), almotriptan 12.5 mg and zolmitriptan 2.5 mg were compared and both demonstrated comparable efficacy. Almotriptan is effective and well tolerated for the acute treatment of menstrual migraine, showing superiority over placebo and comparable efficacy to other triptans. Frovatriptan may reduce recurrence more effectively, but larger, dedicated trials are needed to confirm these findings."

Clinical • Review • CNS Disorders • Migraine • Pain

Melting Transitions in Small Aluminum Clusters Simulated with Energies Approaching DFT Accuracy. (PubMed, J Chem Theory Comput) - "These energies are then fitted to an accuracy of 10 meV/atom or better with an Allegro E(3)-equivariant neural network potential...The simulated heat capacity of these clusters, in particular Al16+, is in qualitative agreement with experiments. We also observe that the melting point of Aln+ clusters with n = 11-16 are well above the bulk melting point (934 K), with the closed-shell Al13- species possessing an exceptionally high melting point close to 2100 K."

Journal

Data: WireFishing-M: A multimodal dataset for deformable cable insertion using tactile, visual, and proprioceptive sensing. (PubMed, Data Brief) - "The dataset captures a robotic wire insertion scenario, where a Franka Emika Panda 7-DOF robotic manipulator equipped with an Allegro Robot Hand and a DIGIT tactile sensor performs repeated cable insertions into a transparent l-shaped PVC pipe (1″ Sch 40 NSF-61)...WireFishing-M enables the development and benchmarking of multimodal models for perception, force estimation, manipulation policy learning, and success detection in deformable object tasks. The complete dataset is publicly available via Harvard Dataverse and is organized to facilitate direct use in robotic learning and simulation frameworks."

Journal

Taxonomic notes on Phaneropterinae and Tettigoniinae (Orthoptera: Tettigoniidae) from the Palaearctic Region. (PubMed, Zootaxa) - "nov., Poecilimon allegro nal, sp...Many species are recorded from new localities. 334 figures are provided."

Journal

A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy. (PubMed, J Pain Res) - "The report proportion varied among triptans, with naratriptan (12.23%) and almotriptan (12.15%) showing the highest rates, while sumatriptan (4.74%) had the lowest...Disproportionality analysis revealed significant signals for almotriptan (ROR=3.34), naratriptan (ROR=2.96), and rizatriptan (ROR=2.41), with almotriptan exhibiting the strongest association...Time-to-onset analysis showed frovatriptan had the earliest median onset (3.5 days), while almotriptan had the longest (284 days)...Clinicians should carefully evaluate cardiovascular risk factors before prescribing triptans and consider alternative treatments for susceptible individuals. Additional prospective studies are required to validate these findings."

Adverse events • Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Ischemic stroke • Migraine • Myocardial Infarction • Pain

Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3. (PubMed, Int J Dermatol) - P2b | "ALLEGRO-2b/3 participants reported greater improvements in ES and AL due to hair loss by Week 48 with the 50-mg ritlecitinib maintenance dose (+/- 200-mg loading dose) versus subtherapeutic 10-mg ritlecitinib."

Journal • Alopecia • Immunology

A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making. (PubMed, Value Health) - P2b | "Ritlecitinib 50 mg QD demonstrated a positive benefit-risk profile compared with placebo in adult patients with AA."

Benefit-risk assessment • Journal • Alopecia • Immunology • Infectious Disease • Oncology • Thrombosis

Improving Aqueous Metal Salt Interactions Using Machine-Learned Interatomic Potentials. (PubMed, J Phys Chem B) - "In this study, we develop machine-learned interatomic potentials (MLIPs) to model aqueous AsCl3 and MgCl2 using the NequIP/Allegro equivariant graph neural network architecture trained on ab initio molecular dynamics (AIMD) and density functional theory data...Our MLIPs achieve energy MAEs < 1 meV/atom and force RMSEs < 40 meV/Å, while providing an O(104) speedup over AIMD. These MLIPs offer a reliable and efficient alternative for modeling trace metal speciation and transport, with implications for improved separation and environmental processes."

Journal

Frova Introducer in Anesthesiology: Friend or Foe? (PubMed, Cureus) - "The patient recovered fully with conservative treatment. Our report highlights the need for caution when using airway exchange catheters in patients with challenging anatomical airways and close post-extubation monitoring."

Journal • Anesthesia • Chronic Obstructive Pulmonary Disease • Endocrine Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Long-term efficacy and complete scalp hair regrowth in patients with alopecia areata receiving ritlecitinib 50 mg QD up to 3 years in the ALLEGRO clinical trial program (EADV 2025) - P2b, P3 | "Conclusion Ritlecitinib 50 mg demonstrated clinically meaningful clinician-reported efficacy up to Month 36-38, supporting the long-term use of ritlecitinib in patients aged ≥12 years with AA. Almost one-third of patients receiving ritlecitinib 50 mg achieved complete scalp hair regrowth (SALT score of 0) at ≥1 time point, with the majority sustaining that response at later visits or remaining at SALT score ≤5."

Clinical • Late-breaking abstract • Alopecia • Immunology • JAK3

Updated integrated safety analysis of ritlecitinib up to ~5 years in patients with alopecia areata (AA) from the ALLEGRO clinical trial program (EADV 2025) - P2, P2a, P2b, P3 | "Ritlecitinib was generally well tolerated up to ~5 years in patients with AA. Safety was consistent with previously reported data."

Clinical • Alopecia • Breast Cancer • Genetic Disorders • Herpes Zoster • Immunology • Infectious Disease • Respiratory Diseases • Skin Cancer • Solid Tumor • Varicella Zoster • JAK3

Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system. (PubMed, PLoS One) - "Positive tinnitus signals were observed for several CGRP inhibitors, except eptinezumab and atogepant, and for all triptans except sumatriptan...However, intra-class analysis identified naratriptan, almotriptan, and frovatriptan as having notable tinnitus signals among triptans, while CGRP inhibitors did not exhibit strong signals for any specific drug. Using real-world data from FAERS and pharmacovigilance methods, this study identified tinnitus signals related to migraine treatments, particularly among certain triptans. These findings provide preliminary evidence for further investigation into the relationship between migraine medications and tinnitus."

Adverse events • Journal • CNS Disorders • Migraine • Otorhinolaryngology • Pain

Kingdom-wide CRISPR guide design with ALLEGRO. (PubMed, Nucleic Acids Res) - "Additionally, we employed a generalized Cas9-ribonucleoprotein delivery system to apply ALLEGRO's sgRNA libraries to untested fungal genomes, such as Rhodotorula araucariae. Our experimental findings, together with cross-validation, demonstrate that ALLEGRO facilitates efficient CRISPR genome editing, enabling the development of universal sgRNA libraries applicable to entire taxonomic groups."

Journal

Machine-learning molecular dynamics simulations of hydration behavior of TMAO zwitterion (ACS-Fall 2025) - "Our ML MD simulations using the Allegro-LAMMPS framework provide insights into TMAO's structural properties and hydration behavior, such as the hydration shell and hydrogen bonding between the TMAO oxygen atom and the hydrogen atoms of surrounding water molecules. The results exhibit close agreement with those obtained from AIMD while achieving a computational speedup of over three orders of magnitude."

Machine learning

Musical neurostimulation improves cognitive function in children with epilepsy and causes electroencephalogram changes. (PubMed, Epilepsy Behav) - "Listening to Mozart's K. 448, Johann Sebastian Bach's Allegro, and Johann Christian Bach's Allegro di Molto is a promising approach for improving the cognitive function of children with epilepsy."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Pediatrics

MS25: Materials Science-Focused Benchmark Data Set for Machine Learning Interatomic Potentials. (PubMed, J Chem Inf Model) - "Five MLIP architectures (MACE, NequIP, Allegro, MTP, and Torch-ANI) are trained and tested, focusing not only on traditional metrics (energies, forces, and stresses) but also explicitly validating derived physical observables such as lattice constants, volumes, and reaction barriers...For researchers looking to choose an MLIP architecture, we suggest selecting equivariant MLIP architectures if the complexity of the system is a challenge. For simple materials problems, auxiliary features such as integration with molecular dynamics engines, trade-offs between computational data set generation cost vs MLIP inference speed, and framework integration may play a more important decision factor than small differences in error metrics that are unlikely to matter for production-level research."

Journal

Apax: A Flexible and Performant Framework for the Development of Machine-Learned Interatomic Potentials. (PubMed, J Chem Inf Model) - "We report that a Gaussian Moment Neural Network model, as implemented in apax, achieves higher accuracy and up to 10 times faster inference times than a performance-optimized Allegro model...Moreover, the inference speeds of the available simulation engines are compared. Finally, to highlight the modularity of apax, an equivariant message-passing model is trained as a shallow ensemble and used to perform uncertainty-driven dynamics."

Journal

Facilitators and Barriers to Mental Health Leaves and Return to Work Among Canadian Teachers. (PubMed, New Solut) - "We interpret these findings through a synthesized framework combining Allegro and Veerman's theory of sickness absence and D'Amato and Zijsrtra's theory of work resumption, highlighting individual, organizational, and societal factors shaping leave and return decisions. With the high cost of teacher absences and critical staffing shortages, we discuss the impacts of these facilitators and barriers and make recommendations for practice for a healthy teaching workforce."

Journal

Chemtrain-Deploy: A Parallel and Scalable Framework for Machine Learning Potentials in Million-Atom MD Simulations. (PubMed, J Chem Theory Comput) - "We validate its performance and scalability using graph neural network architectures, including MACE, Allegro, and PaiNN, applied to a variety of systems such as liquid-vapor interfaces, crystalline materials, and solvated peptides. Our results highlight the practical utility of chemtrain-deploy for real-world, high-performance simulations and provide guidance for MLP architecture selection and future design."

Journal • Pain

Improving beta-amyloid PET productivity: Exploring early and short acquisition windows for 18F-NAV4694 PET to increase clinical throughput. (SNMMI 2025) - " 38 AIBL participants underwent dynamic 18F-NAV4694 imaging on a Philips Allegro scanner... For each regression, the equation and coefficient of determination (R2) were: estCL50-70 = 1.03 CL50-60 + 0.83 (R2=0.999). estCL50-70 = 1.14 CL40-50 + 2.56 (R2=0.997). estCL50-70 = 1.33 CL30-40 + 6.17 (R2=0.993)."

Amyloid PET • Clinical • Alzheimer's Disease • CNS Disorders